<DOC>
	<DOCNO>NCT01332266</DOCNO>
	<brief_summary>The purpose study determine whether patient Platinum-Resistant Squamous Cell Carcinoma Head Neck receive either E7050 administer Cetuximab Cetuximab alone experience great benefit</brief_summary>
	<brief_title>E7050 Combination With Cetuximab Versus Cetuximab Alone Treatment Platinum-Resistant Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description>This open-label , multicenter , randomize study consist Phase Ib : safety run-in period 3 ascending dos E7050 combination Cetuximab ; Phase II portion : randomize 2-arm period . Approximately 95 patient Platinum-Resistant Squamous Cell Carcinoma head neck enrol study ( 10-15 patient Phase Ib portion 80 patient Phase II portion ) . Patients participate either Phase Ib Phase II portion study . In phase II portion , Patients receive study treatment ( E7050 plus Cetuximab Cetuximab alone ) approximately six 28-day cycle ( 24 week ) . Beyond 24 week , patient experience clinical benefit may continue E7050 plus cetuximab , cetuximab alone E7050 alone ( Arm 1 ) , may continue cetuximab alone ( Arm 2 ) , depend original randomization treatment arm , long clinical benefit sustain treatment well tolerate .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Platinumresistant ( defined failure respond treatment platinum agent recurrence disease initial response platinum within 12 month complete therapy ) , locally advanced , recurrent and/or metastatic SCCHN , untreatable surgical resection radiation therapy ; ECOG PS 02 ; Blood pressure must wellcontrolled . Patients must history hypertensive crisis hypertensive encephalopathy ; Adequate end organ function Exclusion Criteria Nasopharyngeal tumor ; Previously receive E7050 , anticmet , antiangiogenic therapy , antiEGFR therapy ( prior antiangiogenic/EGFR therapy permit Phase Ib . Prior cetuximab permit administered combination radiation ; Presence brain metastasis , unless patient received adequate treatment least 4 week prior randomization , stable , asymptomatic , steroid least 4 week prior randomization ; Palliative radiotherapy permit throughout study period ; Clinically significant hemoptysis ; Serious nonhealing wound , ulcer , active bone fracture ; Major surgical procedure , open biopsy significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study ; Clinically significant gastrointestinal bleeding within 6 month prior first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Cancer</keyword>
	<keyword>head neck</keyword>
	<keyword>squamous cell carcinoma head neck</keyword>
	<keyword>phase I</keyword>
	<keyword>phase II</keyword>
</DOC>